VT3989
vivace therapeutics
['mesothelioma', 'solid tumor']
7 of 69 patients had radiological partial responses that persisted up to at least 21 months, indicating tumor shrinkage, while 34 had stable disease. benefits observed in patients with both mesothelioma &amp; other solid tumors, both with and without nf2 mutations. (ct006) #aacr23
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789